Members of the Tumor Microenvironment and Metastasis research program at IU Simon Comprehensive Cancer Center focus on cancer cell–stroma interactions, systemic consequences of metastatic disease, and basic science that leads to clinical trials.
Raghava Kurup R, Oakes EK, Manning AC, Mukherjee P, Vadlamani P and Hundley HA (2022) RNA binding by ADAR3 inhibits adenosine-to-inosine editing and promotes expression of the immune response protein MAVS, JBC, 2022 Jul 15:102267. doi: 10.1016/j.jbc.2022.102267.
Ray U, Jung DB, Jin L, Xiao Y, Dasari S (TT), Sarkar Bhattacharya S, Thirusangu P, Staub JK, Roy D, Roy B, Weroha SJ, Hou X, Purcell JW, Bakkum-Gamez JN, Kaufmann SH, Kannan N, Mitra AK , Shridhar V. Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer. Cancer Res. 2022 MAR 15; 82(6):1038-1054. DOI: 10.1158/0008-5472.CAN-21-0622. PubMed PMID: 34654724; PMCID: PMC8930558.
Kumar B, Adebayo AK, Prasad M, Capitano ML, Wang R, Bhat-Nakshatri P, Anjanappa M, Simpson E, Chen D, Liu Y, Schilder JM, Colter AB, Maguire C, Temm CJ, Sandusky G, Doud EH, Wijeratne AB, Mosley AL, Broxmeyer HE and Nakshatri H. (2022). Tumor collection/processing under physioxia uncovers highly relevant signaling networks and drug sensitivity. Science Advances 8:eabh3375. Impact factor 14.2
Su X, et al. PCNA inhibition enhances the cytotoxicity of β-lapachone in NQO1-Positive cancer cells by augmentation of oxidative stress-induced DNA damage. Cancer Lett. 2021 Oct 28;519:304-314.
Wilson DM 3rd, et al. Fragment- and structure-based drug discovery for developing therapeutic agents targeting the DNA Damage Response. Prog Biophys Mol Biol. 2021 Aug;163:130-142.
Gampala S, Shah F, Lu X, Moon H, Babb O, Ganesh NU, Sandusky. G, Hulsey E, Armstrong, L, Mosely AL, Han B, Ivan M, Yeh J-R J, Kelley MR, Zhang C^, Fishel ML^. Ref-1 redox activity alters cancer cell metabolism in pancreatic cancer: Exploiting this novel finding as a potential target. J Exp Clin Cancer Res (2021) 40: https://doi.org/10.1186/s13046-021-02046-x. PMID: 34376225 ^Co-corresponding authors
Miller SA, et al. LSD1 and Aberrant DNA Methylation Mediate Persistence of Enteroendocrine Progenitors That Support BRAF-Mutant Colorectal Cancer. Cancer Res. 2021 Jul 15;81(14):3791-3805.
Chahoud J, Gleber-Netto FO, McCormick BZ, Rao P, Lu X, Guo M, Morgan MB, Chu RA, Martinez-Ferrer M, Eterovic AK, Pickering CR, Pettaway CA. Whole Exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2021 May 1;27(9):2560-2570. doi: 10.1158/1078-0432.CCR-20-4004. Epub 2021 Jan 13. PubMed PMID: 33441293.
Sun X, Li K, Zha R, Liu S, Fan Y, Wu D, Hase M, Aryal UK, Lin CC, Li BY, Yokota H.Theranostics. Preventing tumor progression to the bone by induced tumor-suppressing MSCs. 2021 Mar 5;11(11):5143-5159. doi: 10.7150/thno.58779. eCollection 2021.PMID: 33859739
Greulich, B.M., Plotnik, J.P., Jerde, T.J., and P.C. Hollenhorst (2021). Toll-like receptor 4 signaling activates ERG function in prostate cancer and provides a therapeutic target. NAR Cancer 3(1): zcaa046.
Harikrishna Nakshatri, PhD, and colleagues are discovering new ways to find out how effective a drug might be against cancer. Their findings have been published in the journal Science Advances. “This paper completely changes the way we need to collect tumor tissues and test for drug sensitivity,” Dr. Nakshatri said.
Nationally recognized for her research in pancreatic cancer, Melissa Fishel, PhD, is interested in understanding how tumors can survive in the presence of stressors by investigating the cancer-driving signaling pathways that contribute to survival.
Dr. Fishel and her team developed spherical 3D tumor models to test different combination therapies. These models are created from patient samples and more closely resemble the structure of real tumors than traditional, single-layer cell cultures.
...the more accurate we can make our model systems, the faster new treatments can move from the lab to real patients.
Melissa Fishel, PhD
